View Future GrowthAzenta 過去の業績過去 基準チェック /06Azentaは11.8%の年平均成長率で業績を伸ばしているが、Life Sciences業界はgrowingで4.4%毎年増加している。売上は成長しており、年平均9.3%の割合である。主要情報11.80%収益成長率-0.73%EPS成長率Life Sciences 業界の成長26.83%収益成長率9.29%株主資本利益率-7.13%ネット・マージン-18.59%前回の決算情報31 Mar 2026最近の業績更新お知らせ • May 08+ 1 more updateAzenta, Inc. Reports Impairment Charges for the Second Quarter Ended March 31, 2026Azenta, Inc. reported Impairment Charges for the second quarter ended March 31, 2026. For the quarter, the company reported Impairment of goodwill and intangible assets of $149,083,000.お知らせ • Apr 30Azenta, Inc. to Report Q2, 2026 Results on May 06, 2026Azenta, Inc. announced that they will report Q2, 2026 results Pre-Market on May 06, 2026お知らせ • Jan 22Azenta, Inc. to Report Q1, 2026 Results on Feb 04, 2026Azenta, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026お知らせ • Nov 13Azenta, Inc. to Report Q4, 2025 Results on Nov 21, 2025Azenta, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 21, 2025お知らせ • Jul 24Azenta, Inc. to Report Q3, 2025 Results on Aug 05, 2025Azenta, Inc. announced that they will report Q3, 2025 results Pre-Market on Aug 05, 2025お知らせ • Apr 25Azenta, Inc. to Report Q2, 2025 Results on May 07, 2025Azenta, Inc. announced that they will report Q2, 2025 results Pre-Market on May 07, 2025すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jul 08Now 21% undervaluedOver the last 90 days, the stock has risen 17% to €21.60. The fair value is estimated to be €27.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 3.1% in a year. Earnings are forecast to grow by 36% in the next year.Recent Insider Transactions • May 27Independent Director recently bought €141k worth of stockOn the 18th of May, William Cornog bought around 10k shares on-market at roughly €14.07 per share. This transaction increased William's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €445k more in shares than they have sold in the last 12 months.Board Change • May 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Dipal Doshi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 08+ 1 more updateAzenta, Inc. Reports Impairment Charges for the Second Quarter Ended March 31, 2026Azenta, Inc. reported Impairment Charges for the second quarter ended March 31, 2026. For the quarter, the company reported Impairment of goodwill and intangible assets of $149,083,000.お知らせ • Apr 30Azenta, Inc. to Report Q2, 2026 Results on May 06, 2026Azenta, Inc. announced that they will report Q2, 2026 results Pre-Market on May 06, 2026お知らせ • Apr 08Azenta, Inc. Announces Executive ChangesAzenta, Inc. announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer. This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market adoption and performance. Ginger Zhou will step down from her role as President of the Multiomics business and will continue to support the Company in an advisory capacity through November 2026 to ensure continuity and a smooth transition as the business advances into its next phase of execution. Mr. Martin most recently served as Chief Executive Officer and a member of the Board of Directors of Maravai Life Sciences, where he led strategic and operational transformation across a multi-segment life sciences platform. Prior to Maravai, he served in senior leadership roles at Danaher Corporation, including Senior Vice President, Genomic Medicines, and President of Integrated DNA Technologies (IDT). Mr. Martin joined Danaher following their 2018 acquisition of IDT, after helping to lead the sale process. Prior to acquisition, Mr. Martin spent more than two decades at IDT in positions of increasing responsibility where he helped drive global expansion through organic and inorganic growth investments, sustaining double-digit growth for the entire period. Mr. Martin holds a bachelor's degree in biochemistry from the University of Iowa.お知らせ • Feb 04Azenta, Inc. Reiterates Earnings Guidance for Full Year Fiscal 2026Azenta, Inc. reiterated earnings guidance for full year fiscal 2026. For the period, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025.お知らせ • Feb 03Azenta, Inc. Announces Resignation of Alan P. Malus from Board of Directors and Member of Human Resources and Compensation Committee, Effective January 29, 2026Azenta, Inc. was notified that Alan P. Malus resigned from the Company's Board of Directors, effective January 29, 2026. Mr. Malus also served as a member of the Human Resources and Compensation Committee. His resignation was due to full time responsibilities with another company, which will prevent him from devoting sufficient time to his duties with the Company.お知らせ • Jan 22Azenta, Inc. to Report Q1, 2026 Results on Feb 04, 2026Azenta, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026お知らせ • Dec 19Azenta, Inc., Annual General Meeting, Jan 28, 2026Azenta, Inc., Annual General Meeting, Jan 28, 2026.お知らせ • Dec 11Azenta, Inc. (NasdaqGS:AZTA) announces an Equity Buyback for $250 million worth of its shares.Azenta, Inc. (NasdaqGS:AZTA) announces a share repurchase program. Under the program, the company will repurchase up to $250 million in common stock. The purpose of the program is to enhance shareholder value and capitalize on undervaluation. The program will be funded from Company’s available cash reserves, operating cash flow, or other sources as determined by management, consistent with the Company’s financial policies. The program will be valid till December 31, 2028.お知らせ • Dec 03Azenta, Inc. announced delayed annual 10-K filingOn 12/02/2025, Azenta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 21Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2026Azenta, Inc. provided earnings guidance for the fiscal year 2026. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025.お知らせ • Nov 13Azenta, Inc. to Report Q4, 2025 Results on Nov 21, 2025Azenta, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 21, 2025お知らせ • Aug 05Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025Azenta, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.お知らせ • Jul 24Azenta, Inc. to Report Q3, 2025 Results on Aug 05, 2025Azenta, Inc. announced that they will report Q3, 2025 results Pre-Market on Aug 05, 2025お知らせ • Jul 03Azenta, Inc Announces Resignation of Violetta Hughes as Chief Accounting Officer, Effective August 2025On June 27, 2025, Azenta, Inc. received notice from Violetta Hughes, Vice President and Chief Accounting Officer (Principal Accounting Officer), of her voluntary resignation from this position and from all director and officer positions with the Company’s subsidiaries, effective August 6, 2025. Ms. Hughes is resigning to pursue opportunities outside of the Company. Ms. Hughes’ resignation is not the result of any disagreement with the Company or its Board of Directors on any matter relating to its operations, policies, or practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures. Ms. Hughes will work through the Separation Date to ensure a smooth transition of her responsibilities.お知らせ • Jun 30+ 4 more updatesAzenta, Inc.(NasdaqGS:AZTA) dropped from Russell 1000 Dynamic IndexAzenta, Inc.(NasdaqGS:AZTA) dropped from Russell 1000 Dynamic Indexお知らせ • May 07Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025Azenta, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.お知らせ • Apr 25Azenta, Inc. to Report Q2, 2025 Results on May 07, 2025Azenta, Inc. announced that they will report Q2, 2025 results Pre-Market on May 07, 2025お知らせ • Apr 10David Wang Cease to Be President of Sample Management Solutions of Azenta, IncOn April 7, 2025, Azenta, Inc. and David Wang, President of Sample Management Solutions, agreed that Mr. Wang's employment with the Company would cease effective April 9, 2025.お知らせ • Jan 31Azenta, Inc. Announces the Election of Dipal Doshi to Its Board of DirectorsAzenta, Inc. announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier January 30, 2025. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. About Dipal Doshi: Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company. Mr. Doshi holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. Dipal also serves on the Board of Directors at ashibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston.お知らせ • Jan 28Azenta, Inc. to Report Q1, 2025 Results on Feb 05, 2025Azenta, Inc. announced that they will report Q1, 2025 results Pre-Market on Feb 05, 2025お知らせ • Dec 18Azenta, Inc., Annual General Meeting, Jan 30, 2025Azenta, Inc., Annual General Meeting, Jan 30, 2025.お知らせ • Nov 25Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector)Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector)Reported Earnings • Nov 14Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023)Full year 2024 results: US$3.09 loss per share (further deteriorated from US$0.19 loss in FY 2023). Revenue: US$656.3m (down 1.3% from FY 2023). Net loss: US$164.2m (loss widened US$151.3m from FY 2023). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • Nov 13+ 1 more updateAzenta, Inc. Announces Chief Financial Officer ChangesAzenta, Inc. named Lawrence Y. Lin as Chief Financial Officer, succeeding Herman Cueto, effective after the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2024 is filed with the Securities and Exchange Commission. Mr. Cueto will remain as an advisor for a period of time to help facilitate a seamless transition. Mr. Lin joins Azenta from GeoStabilization International LLC ("GSI"), and brings over twenty years of finance experience, including previously holding senior finance roles at PHC Holdings and Danaher. Before joining GSI, Mr. Lin was Senior Vice President of Finance Operations at PHC Holdings Corporation. Prior roles include Vice President of Finance for North America (CFO) and Global Functions at LivaNova, and Vice President of Finance Operations at KaVo Kerr. Mr. Lin holds a bachelor's degree in finance from California State University, Fullerton.お知らせ • Nov 05+ 1 more updateAzenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024Azenta, Inc. announced that they will report Q4, 2024 results After-Market on Nov 12, 2024お知らせ • Nov 02Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing TestAzenta, Inc. announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of PacBio's Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads. Performed within GENEWIZ from Azenta Life Sciences CLIA certified and CAP accredited clinical genomics laboratory, the test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches. This allows for a view of the genome with unprecedented comprehensiveness.お知らせ • Sep 04+ 1 more updateAzenta, Inc. Announces Management ChangesAzenta, Inc. announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, exceeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. Previously, he served as CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues and leading its IPO from owners KKR & Co. He also held a variety of senior executive roles in leading life sciences companies, including at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health Inc., where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.Breakeven Date Change • Aug 15Forecast to breakeven in 2026The 6 analysts covering Azenta expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$1.82m in 2026. Average annual earnings growth of 95% is required to achieve expected profit on schedule.New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$16m net loss in 2 years). Share price has been volatile over the past 3 months (6.7% average weekly change).Breakeven Date Change • Aug 07No longer forecast to breakevenThe 5 analysts covering Azenta no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$3.22m in 2026. New consensus forecast suggests the company will make a loss of US$10.5m in 2026.お知らせ • Jul 25Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024Azenta, Inc. announced that they will report Q3, 2024 results After-Market on Aug 06, 2024お知らせ • May 10Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024Azenta, Inc. provided earnings guidance for the full fiscal year 2024. The company expected revenue in the range of $659 million to $671 million, due to the timing of B Medical revenue.Reported Earnings • May 09Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023)Second quarter 2024 results: US$2.47 loss per share (further deteriorated from US$0.029 loss in 2Q 2023). Revenue: US$159.1m (up 7.2% from 2Q 2023). Net loss: US$136.9m (loss widened US$134.9m from 2Q 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • May 09+ 1 more updateStephen Schwartz to Retire as CEO of Azenta, IncAzenta, Inc. announced a CEO succession plan, under which CEO Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CEO until a successor is appointed to ensure a smooth transition. Dr. Schwartz's retirement follows a discussion with the Board as part of the company's active succession planning process. In connection with that process, the Board has initiated a search to identify Azenta's next CEO, and has engaged Heidrick & Struggles, a leading executive search firm, to assist in the process of identifying and evaluating candidates. Dr. Stephen Schwartz joined Azenta in April 2010 as President and was appointed CEO in August 2010. During his tenure as CEO of Azenta, Dr, Schwartz oversaw the $3 billion sale of Azenta's Semiconductor Solutions business to Thomas H. Lee Partners, and established Azenta as a global, pure-play life sciences company with annual revenue of over $600 million. From November 2018 to January 2024, Dr. Schwartz served on the board of directors of Spire Inc., a publicly traded natural gas company. Dr. Schwartz received his BSEE, MSEE, and Ph.D. in electrical engineering from Purdue University. He also holds an MBA from the University of Chicago.Buy Or Sell Opportunity • May 07Now 22% overvaluedOver the last 90 days, the stock has fallen 15% to €51.50. The fair value is estimated to be €42.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.お知らせ • May 03Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024Azenta, Inc. announced that they will report Q2, 2024 results After-Market on May 08, 2024Buy Or Sell Opportunity • Apr 13Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to €52.50. The fair value is estimated to be €43.54, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (US$27m net loss next year).New Risk • Feb 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$17m Forecast net loss in 2 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Board Change • Feb 06High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Martin Madaus was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 02+ 1 more updateAzenta, Inc. Announces the Launch of the BioArc UltraAzenta, Inc. announced the launch of the BioArc™ Ultra (the Ultra), a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance for large-scale sample management with the potential to forever change the landscape of biorepositories. The Ultra delivers significant operational efficiency benefits, including footprint, labor and electricity cost savings as compared to other commercially available systems, while enabling customers to further their global carbon emissions reduction goals. The Ultra is an innovative evolution stemming from Azenta's well-established and automated ultracold system product range. The Ultra features a breakthrough eco-friendly cooling system utilizing natural air rather than manufactured, ozone-depleting refrigerants, enabling a zero ozone depletion potential (ODP) and zero global warming potential (GWP), two factors that are key to sustainability needs and initiatives within life sciences industries and applications. The innovative, eco-friendly, refrigeration technology also reduces electric power consumption by 70% with a similar reduction in storage system footprint (compared to other commercially available manual options for similar storage capacity). The Ultra is now available for order and will be featured at the Azenta exhibit booth #909 at Society for Laboratory Automation and Screening (SLAS) 2024 International Conference, February 3-7 in Boston, Massachusetts. Azenta is also hosting a panel discussion entitled "Sustainable Excellence: Charting the Course of an Energy-Efficient Sample Storage Future" taking place at SLAS on February 5 from 12:00 – 1:00PM in Room 103. This discussion will highlight the savings and sustainability of the Ultra, as well as considerations for a sustainable and cost-effective future for sample storage practices.お知らせ • Jan 26Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024Azenta, Inc. announced that they will report Q1, 2024 results After-Market on Feb 07, 2024お知らせ • Jan 19Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024Azenta, Inc. provided earnings guidance for the fiscal year 2024 . For the year, company expects revenue growth to be in range of 5% to 8%.お知らせ • Jan 18Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, IncOn January 10, 2024, Ellen M. Zane notified Azenta, Inc. that she has decided not to stand for election to the Board of Directors of the Company at the 2024 Annual Meeting of the Company’s Stockholders to be held on January 30, 2024, and, as a result, Ms. Zane will no longer be a nominee for re-election at the 2024 Annual Meeting and her tenure as a director will end as of the 2024 Annual Meeting. No other nominee for election at the 2024 Annual Meeting will be named in place of Ms. Zane and the size of the Board will be reduced from ten to nine members effective as of the 2024 Annual Meeting. Ms. Zane’s decision not to stand for election was not due to any disagreement with the Company.お知らせ • Dec 16Azenta, Inc., Annual General Meeting, Jan 30, 2024Azenta, Inc., Annual General Meeting, Jan 30, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect ten director nominees; to approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers; to recommend the frequency of holding an advisory vote on executive compensation; to ratify PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the 2024 fiscal year; and to consider any other business as may properly come before the meeting.お知らせ • Nov 15Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024Azenta, Inc. provided earnings guidance for the Full Year Fiscal 2024. For the year, the company expects Total revenue is expected to be in the range of $696 to $718 million, reflecting total organic revenue growth in the range of 5% to 8% relative to Fiscal 2023.Reported Earnings • Nov 14Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022)Full year 2023 results: US$0.19 loss per share (further deteriorated from US$0.15 loss in FY 2022). Revenue: US$665.1m (up 20% from FY 2022). Net loss: US$12.9m (loss widened 14% from FY 2022). Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Nov 09Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023Azenta, Inc. announced that they will report Q4, 2023 results After-Market on Nov 13, 2023お知らせ • Nov 02Politan Capital Provides Information to the ShareholdersOn November 1, 2023, Politan Capital Management LP announced that it has entered into a non-disclosure agreement with Azenta, Inc and is currently engaging in discussions with the Company’s management and board of directors concerning the Company’s business, strategies and corporate governance. Coincident with these discussions, due to the November 2, 2023 nomination deadline in the Amended and Restated Bylaws of the Company (the Bylaws), on October 30, 2023, Politan Capital NY LLC, in compliance with the Bylaws, submitted to the Company its formal notice to nominate candidates for election to the Board, one of whom is Politan’s Managing Partner and Chief Investment Officer Quentin Koffey.お知らせ • Sep 28Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023Azenta, Inc. announced that Herman Cueto will join Azenta as Chief Financial Officer, effective October 16, 2023. Mr. Cueto, who comes from BD (Becton, Dickinson and Company), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Robertson is expected to remain the Company’s Principal Financial Officer until the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023, after which time, Mr. Cueto will become the Company’s Principal Financial Officer. Mr. Cueto, age 49, previously served as the Senior Vice President of Finance of Becton, Dickinson and Company (NYSE: BDX), since June 2021, and served in senior financial and operations roles at Becton, Dickinson and Company since December 2017 including as the Senior Vice President and Chief Financial Officer of Becton, Dickinson and Company’s Medical Segment from January 2021 to June 2021. Prior to that, Mr. Cueto was at C.R. Bard, Inc. for fourteen years, most recently as Vice President and Group CFO. Mr. Cueto earned a Bachelor of Science and Master’s degrees from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey.お知らせ • Sep 27Azenta, Inc. Announces Executive Vice President Changes, Effective October 16, 2023Azenta, Inc. announced that Herman Cueto will join Azenta as Executive Vice President, effective October 16, 2023. Mr. Cueto, who comes from BD (Becton, Dickinson and Company), will succeed Azenta Executive Vice President Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Cueto, age 49, previously served as the Senior Vice President of Finance of Becton, Dickinson and Company (NYSE: BDX), since June 2021, and served in senior financial and operations roles at Becton, Dickinson and Company since December 2017 including as the Senior Vice President and Chief Financial Officer of Becton, Dickinson and Company’s Medical Segment from January 2021 to June 2021. Prior to that, Mr. Cueto was at C.R. Bard, Inc. for fourteen years, most recently as Vice President and Group CFO. Mr. Cueto earned a Bachelor of Science and Master’s degrees from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey.お知らせ • Sep 17Politan Capital Management Engages in Discussions with AzentaOn September 14, 2023, Politan Capital Management LP announced that it has engaged and intends to continue to engage in discussions with certain members of Azenta, Inc.’s board of directors and management team regarding the Company’s business, operations, financial condition, strategic plans, governance, as well as other matters related to the Company, and intends to and may also engage with stockholders, industry analysts and other interested parties with respect to the foregoing.New Risk • Aug 17New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €466k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Significant insider selling over the past 3 months (€466k sold).Recent Insider Transactions • Aug 16Insider recently sold €369k worth of stockOn the 10th of August, Robin Vacha sold around 7k shares on-market at roughly €49.93 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €283k more than they sold in the last 12 months.Reported Earnings • Aug 09Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022)Third quarter 2023 results: US$0.039 loss per share (improved from US$0.094 loss in 3Q 2022). Revenue: US$165.9m (up 25% from 3Q 2022). Net loss: US$2.46m (loss narrowed 65% from 3Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 3% per year.お知らせ • Aug 09+ 1 more updateAzenta, Inc. Revises Revenue Guidance for the Full Year of 2023Azenta, Inc. revised revenue guidance for the full year of 2023. For the full year, the company is narrowing its expectation for revenue to be in the range of $648 million to $665 million, consistent with growth of approximately 17% to 20% year over year.お知らせ • Aug 04Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023Azenta, Inc. announced that they will report Q3, 2023 results After-Market on Aug 08, 2023Breakeven Date Change • May 14Forecast breakeven date pushed back to 2025The 5 analysts covering Azenta previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 45% per year to 2024. The company is expected to make a profit of US$6.35m in 2025. Average annual earnings growth of 100% is required to achieve expected profit on schedule.Reported Earnings • May 10Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022)Second quarter 2023 results: US$0.029 loss per share (further deteriorated from US$0.024 loss in 2Q 2022). Revenue: US$148.4m (up 2.0% from 2Q 2022). Net loss: US$1.99m (loss widened 9.6% from 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • May 10Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023Azenta, Inc. provided earnings guidance for the third quarter of fiscal year 2023. For the period, the company expected revenue to be in the range of $150 to $168 million. GAAP diluted loss per share from continuing operations is expected to be in the range of $0.29 to $0.19.お知らせ • May 04Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023Azenta, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023Reported Earnings • Feb 09First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022)First quarter 2023 results: US$0.15 loss per share (down from US$0.038 profit in 1Q 2022). Revenue: US$178.4m (up 28% from 1Q 2022). Net loss: US$11.2m (down 493% from profit in 1Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.お知らせ • Feb 09Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023Azenta, Inc. provided earnings guidance for the second quarter of fiscal year 2023. For the period, the company expected revenue to be in the range of $156 to $171 million. GAAP diluted loss per share from continuing operations is expected to be in the range of $0.24 to $0.16.お知らせ • Feb 07Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023Azenta, Inc. announced that they will report Q1, 2023 results After-Market on Feb 08, 2023お知らせ • Feb 04Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd on February 3, 2023. CEO and co-founder, Neil Benn will continue to lead the business as part of the Consumables and Instruments business within the Life Sciences Products segment.Azenta, Inc. (NasdaqGS:AZTA) completed the acquisition of Ziath Ltd on February 3, 2023.お知らせ • Feb 03Azenta, Inc. Announces Election of DirectorsAzenta, Inc. announced that at its Annual Meeting of the stockholders held on January 31, 2023, approved the election of Tina S. Nova and Dorothy E. Puh y as Directors.お知らせ • Dec 22Azenta, Inc., Annual General Meeting, Jan 31, 2023Azenta, Inc., Annual General Meeting, Jan 31, 2023, at 10:00 Eastern Standard Time. Agenda: To elect ten director nominees; to approve, by a non-binding advisory vote, the compensation of the company’s named executive officers as disclosed in this proxy statement; and to ratify pricewaterhousecoopers llp as the company’s independent registered accounting firm for the 2023 fiscal year.Reported Earnings • Nov 16Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021)Full year 2022 results: US$0.15 loss per share (improved from US$0.39 loss in FY 2021). Revenue: US$555.5m (up 8.1% from FY 2021). Net loss: US$11.3m (loss narrowed 61% from FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Recent Insider Transactions • Aug 23Executive VP & COO recently bought €500k worth of stockOn the 19th of August, Matthew McManus bought around 9k shares on-market at roughly €57.92 per share. This was the largest purchase by an insider in the last 3 months. This was Matthew's only on-market trade for the last 12 months.Reported Earnings • Aug 11Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021)Third quarter 2022 results: US$0.094 loss per share (down from US$0.53 profit in 3Q 2021). Revenue: US$132.7m (down 58% from 3Q 2021). Net loss: US$7.02m (down 118% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Reported Earnings • May 11Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021)Second quarter 2022 results: US$0.024 loss per share (down from US$0.32 profit in 2Q 2021). Revenue: US$145.5m (down 49% from 2Q 2021). Net loss: US$1.82m (down 108% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Buying Opportunity • May 07Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.9%. The fair value is estimated to be €87.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Feb 09First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2022 results: EPS: US$0.038 (down from US$0.36 in 1Q 2021). Revenue: US$139.7m (down 44% from 1Q 2021). Net income: US$2.86m (down 89% from 1Q 2021). Profit margin: 2.0% (down from 11% in 1Q 2021). Revenue exceeded analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 15%, compared to a 16% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Breakeven Date Change • Dec 03Forecast breakeven date pushed back to 2023The 5 analysts covering Azenta previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 81% to 2022. The company is expected to make a profit of US$59.6m in 2023. Average annual earnings growth of 90% is required to achieve expected profit on schedule.お知らせ • Dec 02+ 1 more updateAzenta, Inc.(NasdaqGS:AZTA) dropped from NASDAQ Composite IndexBrooks Automation, Inc. has been removed from NASDAQ Composite Index.Upcoming Dividend • Nov 25Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 23 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.7%).Recent Insider Transactions • Nov 16Independent Director recently sold €282k worth of stockOn the 12th of November, Michael Rosenblatt sold around 3k shares on-market at roughly €99.69 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months.Reported Earnings • Nov 11Full year 2021 earnings released: US$0.39 loss per share (vs US$0.88 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: US$513.7m (down 43% from FY 2020). Net loss: US$28.9m (down 144% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 61% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 7 highly experienced directors. Independent Director Erica McLaughlin was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 7 highly experienced directors. Independent Director Erica McLaughlin was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 30Brooks Automation, Inc. Introduces Azenta Life Sciences to Advance Innovative Sample SolutionsBrooks Automation, Inc. announced Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta"). Azenta will bring together company's existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions. The life sciences industry will benefit from the Azenta portfolio and vision with the integration of industry-leading capabilities within automated ultra-cold sample storage and sample repository solutions, sample sourcing and genomic services, data management and informatics, and consumables and instruments.Valuation Update With 7 Day Price Move • Sep 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to €89.50, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 32x in the Semiconductor industry in Germany. Total returns to shareholders of 217% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.07 per share.収支内訳Azenta の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:BA3 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26596-1112503431 Dec 25595262523230 Sep 25594242623030 Jun 25586-272613131 Mar 25586-282643131 Dec 24579-242633130 Sep 24573-242633230 Jun 24595-212733131 Mar 24616-232843331 Dec 23628-92893430 Sep 23551-82643230 Jun 23630-213023331 Mar 23597-262853031 Dec 22594-252792930 Sep 22555-112512830 Jun 22555-282672631 Mar 22551-232672531 Dec 21535-292612430 Sep 21514-292522230 Jun 21114-69183-1031 Mar 21205-53185-231 Dec 20296-37183930 Sep 20389-261901830 Jun 20850412325931 Mar 20834282245931 Dec 19812162175830 Sep 19334-611571730 Jun 1974131945431 Mar 1971071825131 Dec 18668721704930 Sep 18632681634730 Jun 18488351544131 Mar 18498471494031 Dec 17510-21464030 Sep 17527111414030 Jun 17669561364631 Mar 17634471324731 Dec 16600-511274930 Sep 16434-851164430 Jun 16549-731235231 Mar 16546-741195231 Dec 15550121175230 Sep 155531411452質の高い収益: BA3は現在利益が出ていません。利益率の向上: BA3は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BA3は利益を出していないが、過去 5 年間で年間11.8%の割合で損失を削減してきた。成長の加速: BA3の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BA3は利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 8.5% ) と比較することは困難です。株主資本利益率高いROE: BA3は現在利益が出ていないため、自己資本利益率 ( -7.13% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/19 20:47終値2026/07/17 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Azenta, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Christopher MuseBarclaysBrett HodessBofA Global ResearchPaul KnightBrean Capital Historical (Janney Montgomery)11 その他のアナリストを表示
お知らせ • May 08+ 1 more updateAzenta, Inc. Reports Impairment Charges for the Second Quarter Ended March 31, 2026Azenta, Inc. reported Impairment Charges for the second quarter ended March 31, 2026. For the quarter, the company reported Impairment of goodwill and intangible assets of $149,083,000.
お知らせ • Apr 30Azenta, Inc. to Report Q2, 2026 Results on May 06, 2026Azenta, Inc. announced that they will report Q2, 2026 results Pre-Market on May 06, 2026
お知らせ • Jan 22Azenta, Inc. to Report Q1, 2026 Results on Feb 04, 2026Azenta, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026
お知らせ • Nov 13Azenta, Inc. to Report Q4, 2025 Results on Nov 21, 2025Azenta, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 21, 2025
お知らせ • Jul 24Azenta, Inc. to Report Q3, 2025 Results on Aug 05, 2025Azenta, Inc. announced that they will report Q3, 2025 results Pre-Market on Aug 05, 2025
お知らせ • Apr 25Azenta, Inc. to Report Q2, 2025 Results on May 07, 2025Azenta, Inc. announced that they will report Q2, 2025 results Pre-Market on May 07, 2025
Buy Or Sell Opportunity • Jul 08Now 21% undervaluedOver the last 90 days, the stock has risen 17% to €21.60. The fair value is estimated to be €27.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 3.1% in a year. Earnings are forecast to grow by 36% in the next year.
Recent Insider Transactions • May 27Independent Director recently bought €141k worth of stockOn the 18th of May, William Cornog bought around 10k shares on-market at roughly €14.07 per share. This transaction increased William's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €445k more in shares than they have sold in the last 12 months.
Board Change • May 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Dipal Doshi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 08+ 1 more updateAzenta, Inc. Reports Impairment Charges for the Second Quarter Ended March 31, 2026Azenta, Inc. reported Impairment Charges for the second quarter ended March 31, 2026. For the quarter, the company reported Impairment of goodwill and intangible assets of $149,083,000.
お知らせ • Apr 30Azenta, Inc. to Report Q2, 2026 Results on May 06, 2026Azenta, Inc. announced that they will report Q2, 2026 results Pre-Market on May 06, 2026
お知らせ • Apr 08Azenta, Inc. Announces Executive ChangesAzenta, Inc. announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer. This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market adoption and performance. Ginger Zhou will step down from her role as President of the Multiomics business and will continue to support the Company in an advisory capacity through November 2026 to ensure continuity and a smooth transition as the business advances into its next phase of execution. Mr. Martin most recently served as Chief Executive Officer and a member of the Board of Directors of Maravai Life Sciences, where he led strategic and operational transformation across a multi-segment life sciences platform. Prior to Maravai, he served in senior leadership roles at Danaher Corporation, including Senior Vice President, Genomic Medicines, and President of Integrated DNA Technologies (IDT). Mr. Martin joined Danaher following their 2018 acquisition of IDT, after helping to lead the sale process. Prior to acquisition, Mr. Martin spent more than two decades at IDT in positions of increasing responsibility where he helped drive global expansion through organic and inorganic growth investments, sustaining double-digit growth for the entire period. Mr. Martin holds a bachelor's degree in biochemistry from the University of Iowa.
お知らせ • Feb 04Azenta, Inc. Reiterates Earnings Guidance for Full Year Fiscal 2026Azenta, Inc. reiterated earnings guidance for full year fiscal 2026. For the period, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025.
お知らせ • Feb 03Azenta, Inc. Announces Resignation of Alan P. Malus from Board of Directors and Member of Human Resources and Compensation Committee, Effective January 29, 2026Azenta, Inc. was notified that Alan P. Malus resigned from the Company's Board of Directors, effective January 29, 2026. Mr. Malus also served as a member of the Human Resources and Compensation Committee. His resignation was due to full time responsibilities with another company, which will prevent him from devoting sufficient time to his duties with the Company.
お知らせ • Jan 22Azenta, Inc. to Report Q1, 2026 Results on Feb 04, 2026Azenta, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026
お知らせ • Dec 19Azenta, Inc., Annual General Meeting, Jan 28, 2026Azenta, Inc., Annual General Meeting, Jan 28, 2026.
お知らせ • Dec 11Azenta, Inc. (NasdaqGS:AZTA) announces an Equity Buyback for $250 million worth of its shares.Azenta, Inc. (NasdaqGS:AZTA) announces a share repurchase program. Under the program, the company will repurchase up to $250 million in common stock. The purpose of the program is to enhance shareholder value and capitalize on undervaluation. The program will be funded from Company’s available cash reserves, operating cash flow, or other sources as determined by management, consistent with the Company’s financial policies. The program will be valid till December 31, 2028.
お知らせ • Dec 03Azenta, Inc. announced delayed annual 10-K filingOn 12/02/2025, Azenta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 21Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2026Azenta, Inc. provided earnings guidance for the fiscal year 2026. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025.
お知らせ • Nov 13Azenta, Inc. to Report Q4, 2025 Results on Nov 21, 2025Azenta, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 21, 2025
お知らせ • Aug 05Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025Azenta, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.
お知らせ • Jul 24Azenta, Inc. to Report Q3, 2025 Results on Aug 05, 2025Azenta, Inc. announced that they will report Q3, 2025 results Pre-Market on Aug 05, 2025
お知らせ • Jul 03Azenta, Inc Announces Resignation of Violetta Hughes as Chief Accounting Officer, Effective August 2025On June 27, 2025, Azenta, Inc. received notice from Violetta Hughes, Vice President and Chief Accounting Officer (Principal Accounting Officer), of her voluntary resignation from this position and from all director and officer positions with the Company’s subsidiaries, effective August 6, 2025. Ms. Hughes is resigning to pursue opportunities outside of the Company. Ms. Hughes’ resignation is not the result of any disagreement with the Company or its Board of Directors on any matter relating to its operations, policies, or practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures. Ms. Hughes will work through the Separation Date to ensure a smooth transition of her responsibilities.
お知らせ • Jun 30+ 4 more updatesAzenta, Inc.(NasdaqGS:AZTA) dropped from Russell 1000 Dynamic IndexAzenta, Inc.(NasdaqGS:AZTA) dropped from Russell 1000 Dynamic Index
お知らせ • May 07Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025Azenta, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.
お知らせ • Apr 25Azenta, Inc. to Report Q2, 2025 Results on May 07, 2025Azenta, Inc. announced that they will report Q2, 2025 results Pre-Market on May 07, 2025
お知らせ • Apr 10David Wang Cease to Be President of Sample Management Solutions of Azenta, IncOn April 7, 2025, Azenta, Inc. and David Wang, President of Sample Management Solutions, agreed that Mr. Wang's employment with the Company would cease effective April 9, 2025.
お知らせ • Jan 31Azenta, Inc. Announces the Election of Dipal Doshi to Its Board of DirectorsAzenta, Inc. announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier January 30, 2025. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. About Dipal Doshi: Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company. Mr. Doshi holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. Dipal also serves on the Board of Directors at ashibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston.
お知らせ • Jan 28Azenta, Inc. to Report Q1, 2025 Results on Feb 05, 2025Azenta, Inc. announced that they will report Q1, 2025 results Pre-Market on Feb 05, 2025
お知らせ • Dec 18Azenta, Inc., Annual General Meeting, Jan 30, 2025Azenta, Inc., Annual General Meeting, Jan 30, 2025.
お知らせ • Nov 25Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector)Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector)
Reported Earnings • Nov 14Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023)Full year 2024 results: US$3.09 loss per share (further deteriorated from US$0.19 loss in FY 2023). Revenue: US$656.3m (down 1.3% from FY 2023). Net loss: US$164.2m (loss widened US$151.3m from FY 2023). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 13+ 1 more updateAzenta, Inc. Announces Chief Financial Officer ChangesAzenta, Inc. named Lawrence Y. Lin as Chief Financial Officer, succeeding Herman Cueto, effective after the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2024 is filed with the Securities and Exchange Commission. Mr. Cueto will remain as an advisor for a period of time to help facilitate a seamless transition. Mr. Lin joins Azenta from GeoStabilization International LLC ("GSI"), and brings over twenty years of finance experience, including previously holding senior finance roles at PHC Holdings and Danaher. Before joining GSI, Mr. Lin was Senior Vice President of Finance Operations at PHC Holdings Corporation. Prior roles include Vice President of Finance for North America (CFO) and Global Functions at LivaNova, and Vice President of Finance Operations at KaVo Kerr. Mr. Lin holds a bachelor's degree in finance from California State University, Fullerton.
お知らせ • Nov 05+ 1 more updateAzenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024Azenta, Inc. announced that they will report Q4, 2024 results After-Market on Nov 12, 2024
お知らせ • Nov 02Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing TestAzenta, Inc. announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of PacBio's Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads. Performed within GENEWIZ from Azenta Life Sciences CLIA certified and CAP accredited clinical genomics laboratory, the test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches. This allows for a view of the genome with unprecedented comprehensiveness.
お知らせ • Sep 04+ 1 more updateAzenta, Inc. Announces Management ChangesAzenta, Inc. announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, exceeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. Previously, he served as CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues and leading its IPO from owners KKR & Co. He also held a variety of senior executive roles in leading life sciences companies, including at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health Inc., where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.
Breakeven Date Change • Aug 15Forecast to breakeven in 2026The 6 analysts covering Azenta expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$1.82m in 2026. Average annual earnings growth of 95% is required to achieve expected profit on schedule.
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$16m net loss in 2 years). Share price has been volatile over the past 3 months (6.7% average weekly change).
Breakeven Date Change • Aug 07No longer forecast to breakevenThe 5 analysts covering Azenta no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$3.22m in 2026. New consensus forecast suggests the company will make a loss of US$10.5m in 2026.
お知らせ • Jul 25Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024Azenta, Inc. announced that they will report Q3, 2024 results After-Market on Aug 06, 2024
お知らせ • May 10Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024Azenta, Inc. provided earnings guidance for the full fiscal year 2024. The company expected revenue in the range of $659 million to $671 million, due to the timing of B Medical revenue.
Reported Earnings • May 09Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023)Second quarter 2024 results: US$2.47 loss per share (further deteriorated from US$0.029 loss in 2Q 2023). Revenue: US$159.1m (up 7.2% from 2Q 2023). Net loss: US$136.9m (loss widened US$134.9m from 2Q 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • May 09+ 1 more updateStephen Schwartz to Retire as CEO of Azenta, IncAzenta, Inc. announced a CEO succession plan, under which CEO Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CEO until a successor is appointed to ensure a smooth transition. Dr. Schwartz's retirement follows a discussion with the Board as part of the company's active succession planning process. In connection with that process, the Board has initiated a search to identify Azenta's next CEO, and has engaged Heidrick & Struggles, a leading executive search firm, to assist in the process of identifying and evaluating candidates. Dr. Stephen Schwartz joined Azenta in April 2010 as President and was appointed CEO in August 2010. During his tenure as CEO of Azenta, Dr, Schwartz oversaw the $3 billion sale of Azenta's Semiconductor Solutions business to Thomas H. Lee Partners, and established Azenta as a global, pure-play life sciences company with annual revenue of over $600 million. From November 2018 to January 2024, Dr. Schwartz served on the board of directors of Spire Inc., a publicly traded natural gas company. Dr. Schwartz received his BSEE, MSEE, and Ph.D. in electrical engineering from Purdue University. He also holds an MBA from the University of Chicago.
Buy Or Sell Opportunity • May 07Now 22% overvaluedOver the last 90 days, the stock has fallen 15% to €51.50. The fair value is estimated to be €42.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.
お知らせ • May 03Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024Azenta, Inc. announced that they will report Q2, 2024 results After-Market on May 08, 2024
Buy Or Sell Opportunity • Apr 13Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to €52.50. The fair value is estimated to be €43.54, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (US$27m net loss next year).
New Risk • Feb 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$17m Forecast net loss in 2 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Board Change • Feb 06High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Martin Madaus was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 02+ 1 more updateAzenta, Inc. Announces the Launch of the BioArc UltraAzenta, Inc. announced the launch of the BioArc™ Ultra (the Ultra), a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance for large-scale sample management with the potential to forever change the landscape of biorepositories. The Ultra delivers significant operational efficiency benefits, including footprint, labor and electricity cost savings as compared to other commercially available systems, while enabling customers to further their global carbon emissions reduction goals. The Ultra is an innovative evolution stemming from Azenta's well-established and automated ultracold system product range. The Ultra features a breakthrough eco-friendly cooling system utilizing natural air rather than manufactured, ozone-depleting refrigerants, enabling a zero ozone depletion potential (ODP) and zero global warming potential (GWP), two factors that are key to sustainability needs and initiatives within life sciences industries and applications. The innovative, eco-friendly, refrigeration technology also reduces electric power consumption by 70% with a similar reduction in storage system footprint (compared to other commercially available manual options for similar storage capacity). The Ultra is now available for order and will be featured at the Azenta exhibit booth #909 at Society for Laboratory Automation and Screening (SLAS) 2024 International Conference, February 3-7 in Boston, Massachusetts. Azenta is also hosting a panel discussion entitled "Sustainable Excellence: Charting the Course of an Energy-Efficient Sample Storage Future" taking place at SLAS on February 5 from 12:00 – 1:00PM in Room 103. This discussion will highlight the savings and sustainability of the Ultra, as well as considerations for a sustainable and cost-effective future for sample storage practices.
お知らせ • Jan 26Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024Azenta, Inc. announced that they will report Q1, 2024 results After-Market on Feb 07, 2024
お知らせ • Jan 19Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024Azenta, Inc. provided earnings guidance for the fiscal year 2024 . For the year, company expects revenue growth to be in range of 5% to 8%.
お知らせ • Jan 18Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, IncOn January 10, 2024, Ellen M. Zane notified Azenta, Inc. that she has decided not to stand for election to the Board of Directors of the Company at the 2024 Annual Meeting of the Company’s Stockholders to be held on January 30, 2024, and, as a result, Ms. Zane will no longer be a nominee for re-election at the 2024 Annual Meeting and her tenure as a director will end as of the 2024 Annual Meeting. No other nominee for election at the 2024 Annual Meeting will be named in place of Ms. Zane and the size of the Board will be reduced from ten to nine members effective as of the 2024 Annual Meeting. Ms. Zane’s decision not to stand for election was not due to any disagreement with the Company.
お知らせ • Dec 16Azenta, Inc., Annual General Meeting, Jan 30, 2024Azenta, Inc., Annual General Meeting, Jan 30, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect ten director nominees; to approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers; to recommend the frequency of holding an advisory vote on executive compensation; to ratify PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the 2024 fiscal year; and to consider any other business as may properly come before the meeting.
お知らせ • Nov 15Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024Azenta, Inc. provided earnings guidance for the Full Year Fiscal 2024. For the year, the company expects Total revenue is expected to be in the range of $696 to $718 million, reflecting total organic revenue growth in the range of 5% to 8% relative to Fiscal 2023.
Reported Earnings • Nov 14Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022)Full year 2023 results: US$0.19 loss per share (further deteriorated from US$0.15 loss in FY 2022). Revenue: US$665.1m (up 20% from FY 2022). Net loss: US$12.9m (loss widened 14% from FY 2022). Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Nov 09Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023Azenta, Inc. announced that they will report Q4, 2023 results After-Market on Nov 13, 2023
お知らせ • Nov 02Politan Capital Provides Information to the ShareholdersOn November 1, 2023, Politan Capital Management LP announced that it has entered into a non-disclosure agreement with Azenta, Inc and is currently engaging in discussions with the Company’s management and board of directors concerning the Company’s business, strategies and corporate governance. Coincident with these discussions, due to the November 2, 2023 nomination deadline in the Amended and Restated Bylaws of the Company (the Bylaws), on October 30, 2023, Politan Capital NY LLC, in compliance with the Bylaws, submitted to the Company its formal notice to nominate candidates for election to the Board, one of whom is Politan’s Managing Partner and Chief Investment Officer Quentin Koffey.
お知らせ • Sep 28Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023Azenta, Inc. announced that Herman Cueto will join Azenta as Chief Financial Officer, effective October 16, 2023. Mr. Cueto, who comes from BD (Becton, Dickinson and Company), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Robertson is expected to remain the Company’s Principal Financial Officer until the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023, after which time, Mr. Cueto will become the Company’s Principal Financial Officer. Mr. Cueto, age 49, previously served as the Senior Vice President of Finance of Becton, Dickinson and Company (NYSE: BDX), since June 2021, and served in senior financial and operations roles at Becton, Dickinson and Company since December 2017 including as the Senior Vice President and Chief Financial Officer of Becton, Dickinson and Company’s Medical Segment from January 2021 to June 2021. Prior to that, Mr. Cueto was at C.R. Bard, Inc. for fourteen years, most recently as Vice President and Group CFO. Mr. Cueto earned a Bachelor of Science and Master’s degrees from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey.
お知らせ • Sep 27Azenta, Inc. Announces Executive Vice President Changes, Effective October 16, 2023Azenta, Inc. announced that Herman Cueto will join Azenta as Executive Vice President, effective October 16, 2023. Mr. Cueto, who comes from BD (Becton, Dickinson and Company), will succeed Azenta Executive Vice President Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Cueto, age 49, previously served as the Senior Vice President of Finance of Becton, Dickinson and Company (NYSE: BDX), since June 2021, and served in senior financial and operations roles at Becton, Dickinson and Company since December 2017 including as the Senior Vice President and Chief Financial Officer of Becton, Dickinson and Company’s Medical Segment from January 2021 to June 2021. Prior to that, Mr. Cueto was at C.R. Bard, Inc. for fourteen years, most recently as Vice President and Group CFO. Mr. Cueto earned a Bachelor of Science and Master’s degrees from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey.
お知らせ • Sep 17Politan Capital Management Engages in Discussions with AzentaOn September 14, 2023, Politan Capital Management LP announced that it has engaged and intends to continue to engage in discussions with certain members of Azenta, Inc.’s board of directors and management team regarding the Company’s business, operations, financial condition, strategic plans, governance, as well as other matters related to the Company, and intends to and may also engage with stockholders, industry analysts and other interested parties with respect to the foregoing.
New Risk • Aug 17New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €466k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Significant insider selling over the past 3 months (€466k sold).
Recent Insider Transactions • Aug 16Insider recently sold €369k worth of stockOn the 10th of August, Robin Vacha sold around 7k shares on-market at roughly €49.93 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €283k more than they sold in the last 12 months.
Reported Earnings • Aug 09Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022)Third quarter 2023 results: US$0.039 loss per share (improved from US$0.094 loss in 3Q 2022). Revenue: US$165.9m (up 25% from 3Q 2022). Net loss: US$2.46m (loss narrowed 65% from 3Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 3% per year.
お知らせ • Aug 09+ 1 more updateAzenta, Inc. Revises Revenue Guidance for the Full Year of 2023Azenta, Inc. revised revenue guidance for the full year of 2023. For the full year, the company is narrowing its expectation for revenue to be in the range of $648 million to $665 million, consistent with growth of approximately 17% to 20% year over year.
お知らせ • Aug 04Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023Azenta, Inc. announced that they will report Q3, 2023 results After-Market on Aug 08, 2023
Breakeven Date Change • May 14Forecast breakeven date pushed back to 2025The 5 analysts covering Azenta previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 45% per year to 2024. The company is expected to make a profit of US$6.35m in 2025. Average annual earnings growth of 100% is required to achieve expected profit on schedule.
Reported Earnings • May 10Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022)Second quarter 2023 results: US$0.029 loss per share (further deteriorated from US$0.024 loss in 2Q 2022). Revenue: US$148.4m (up 2.0% from 2Q 2022). Net loss: US$1.99m (loss widened 9.6% from 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • May 10Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023Azenta, Inc. provided earnings guidance for the third quarter of fiscal year 2023. For the period, the company expected revenue to be in the range of $150 to $168 million. GAAP diluted loss per share from continuing operations is expected to be in the range of $0.29 to $0.19.
お知らせ • May 04Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023Azenta, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023
Reported Earnings • Feb 09First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022)First quarter 2023 results: US$0.15 loss per share (down from US$0.038 profit in 1Q 2022). Revenue: US$178.4m (up 28% from 1Q 2022). Net loss: US$11.2m (down 493% from profit in 1Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
お知らせ • Feb 09Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023Azenta, Inc. provided earnings guidance for the second quarter of fiscal year 2023. For the period, the company expected revenue to be in the range of $156 to $171 million. GAAP diluted loss per share from continuing operations is expected to be in the range of $0.24 to $0.16.
お知らせ • Feb 07Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023Azenta, Inc. announced that they will report Q1, 2023 results After-Market on Feb 08, 2023
お知らせ • Feb 04Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd on February 3, 2023. CEO and co-founder, Neil Benn will continue to lead the business as part of the Consumables and Instruments business within the Life Sciences Products segment.Azenta, Inc. (NasdaqGS:AZTA) completed the acquisition of Ziath Ltd on February 3, 2023.
お知らせ • Feb 03Azenta, Inc. Announces Election of DirectorsAzenta, Inc. announced that at its Annual Meeting of the stockholders held on January 31, 2023, approved the election of Tina S. Nova and Dorothy E. Puh y as Directors.
お知らせ • Dec 22Azenta, Inc., Annual General Meeting, Jan 31, 2023Azenta, Inc., Annual General Meeting, Jan 31, 2023, at 10:00 Eastern Standard Time. Agenda: To elect ten director nominees; to approve, by a non-binding advisory vote, the compensation of the company’s named executive officers as disclosed in this proxy statement; and to ratify pricewaterhousecoopers llp as the company’s independent registered accounting firm for the 2023 fiscal year.
Reported Earnings • Nov 16Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021)Full year 2022 results: US$0.15 loss per share (improved from US$0.39 loss in FY 2021). Revenue: US$555.5m (up 8.1% from FY 2021). Net loss: US$11.3m (loss narrowed 61% from FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Aug 23Executive VP & COO recently bought €500k worth of stockOn the 19th of August, Matthew McManus bought around 9k shares on-market at roughly €57.92 per share. This was the largest purchase by an insider in the last 3 months. This was Matthew's only on-market trade for the last 12 months.
Reported Earnings • Aug 11Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021)Third quarter 2022 results: US$0.094 loss per share (down from US$0.53 profit in 3Q 2021). Revenue: US$132.7m (down 58% from 3Q 2021). Net loss: US$7.02m (down 118% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Reported Earnings • May 11Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021)Second quarter 2022 results: US$0.024 loss per share (down from US$0.32 profit in 2Q 2021). Revenue: US$145.5m (down 49% from 2Q 2021). Net loss: US$1.82m (down 108% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Buying Opportunity • May 07Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.9%. The fair value is estimated to be €87.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Feb 09First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2022 results: EPS: US$0.038 (down from US$0.36 in 1Q 2021). Revenue: US$139.7m (down 44% from 1Q 2021). Net income: US$2.86m (down 89% from 1Q 2021). Profit margin: 2.0% (down from 11% in 1Q 2021). Revenue exceeded analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 15%, compared to a 16% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Breakeven Date Change • Dec 03Forecast breakeven date pushed back to 2023The 5 analysts covering Azenta previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 81% to 2022. The company is expected to make a profit of US$59.6m in 2023. Average annual earnings growth of 90% is required to achieve expected profit on schedule.
お知らせ • Dec 02+ 1 more updateAzenta, Inc.(NasdaqGS:AZTA) dropped from NASDAQ Composite IndexBrooks Automation, Inc. has been removed from NASDAQ Composite Index.
Upcoming Dividend • Nov 25Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 23 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.7%).
Recent Insider Transactions • Nov 16Independent Director recently sold €282k worth of stockOn the 12th of November, Michael Rosenblatt sold around 3k shares on-market at roughly €99.69 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months.
Reported Earnings • Nov 11Full year 2021 earnings released: US$0.39 loss per share (vs US$0.88 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: US$513.7m (down 43% from FY 2020). Net loss: US$28.9m (down 144% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 61% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 7 highly experienced directors. Independent Director Erica McLaughlin was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 7 highly experienced directors. Independent Director Erica McLaughlin was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 30Brooks Automation, Inc. Introduces Azenta Life Sciences to Advance Innovative Sample SolutionsBrooks Automation, Inc. announced Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta"). Azenta will bring together company's existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions. The life sciences industry will benefit from the Azenta portfolio and vision with the integration of industry-leading capabilities within automated ultra-cold sample storage and sample repository solutions, sample sourcing and genomic services, data management and informatics, and consumables and instruments.
Valuation Update With 7 Day Price Move • Sep 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to €89.50, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 32x in the Semiconductor industry in Germany. Total returns to shareholders of 217% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.07 per share.